September 1, 2008
NeuroDiscovery released positive results from a phase II trial of NSL-101 for the treatment of periodontitis. This double-blind, randomized, controlled study enrolled 50 subjects in Lima, Peru. The subjects received NSL-101 gel (5%) or lidocaine (5%), the standard analgesic, during scaling and root planing procedures. The primary endpoint was pain intensity, as measured by patients on the Visual Analog Scale (VAS) and Verbal Rating Scale (VRS). Overall, the efficacy of NSL-101 was comparable to that of lidocaine. NSL-101 produced numerically superior analgesia and duration of action compared to lidocaine, however, the differences were not statistically significant. Treatment was well tolerated and there were no reports of drug-related serious adverse events. Based on the results, NeuroDiscovery plans to continue with the development of NSL-101.